<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856059</url>
  </required_header>
  <id_info>
    <org_study_id>21-5167</org_study_id>
    <nct_id>NCT04856059</nct_id>
  </id_info>
  <brief_title>Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI</brief_title>
  <acronym>FIESTA-MRI</acronym>
  <official_title>Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vancouver General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Libin Cardiovascular Institute of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether cardiac MRI T1 and T2 mapping improves our ability to detect&#xD;
      early abnormalities in the heart in patients with Fabry disease and identify patients at&#xD;
      increase risk of adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fabry disease is an inherited disorder that affects many organs in the body, including the&#xD;
      heart. Men and women are both affected, with average life expectancy reduced by 10-20 years.&#xD;
      The heart muscle can become thick and scarred in over half of patients, eventually resulting&#xD;
      in heart failure, abnormal rhythm and death. The focus of this study will be on improving the&#xD;
      detection of early heart disease before irreversible damage has occurred in order to improve&#xD;
      patient outcomes.&#xD;
&#xD;
      It is hypothesized that new cardiac MRI techniques called T1 and T2 mapping will improve the&#xD;
      ability to detect early abnormalities in the heart. Early detection of cardiac disease may&#xD;
      enable a personalized treatment approach, potentially improving patient outcomes. The results&#xD;
      of the study will identify which patients might benefit from early initiation of treatment to&#xD;
      prevent bad outcomes in the future by using cardiac MRI to identify those at higher risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>cardiac MRI</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>5 years</time_frame>
    <description>MACE will be assessed as a composite endpoint defined by the development on one or more of events such as sustained ventricular tachycardia (VT), severe bradycardia, heart failure hospitalization and cardiac death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The FAbry STabilization indEX (FASTEX) score</measure>
    <time_frame>3 years</time_frame>
    <description>FAbry STabilization indEX (FASTEX) score will be evaluated to assess clinical stability or progression of Fabry disease at follow-up.&#xD;
FASTEX score change of ≥20% will be considered an indication of clinical worsening at follow-up.&#xD;
Minimum value 0%. No maximum value. Higher score change indicates worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Cardiac MRI, ECG and Blood Biomarkers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Additional sequences will be performed during routine clinical cardiac MRI and additional blood samples will be collected during routine blood work.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac MRI, ECG/Holter and Blood Biomarkers</intervention_name>
    <description>Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up</description>
    <arm_group_label>Cardiac MRI, ECG and Blood Biomarkers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fabry disease;&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of myocardial infarction;&#xD;
&#xD;
          -  Contraindication to MRI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate Hanneman</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kate Hanneman</last_name>
    <phone>647-964-1714</phone>
    <email>kate.hanneman@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Hanneman, MD</last_name>
      <phone>416-323-6400</phone>
      <phone_ext>5521</phone_ext>
      <email>Kate.Hanneman@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry disease</keyword>
  <keyword>Fabry cardiomyopathy</keyword>
  <keyword>cardiac MRI</keyword>
  <keyword>CMR</keyword>
  <keyword>T1 mapping</keyword>
  <keyword>T2mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

